I-MAB Analyst Ratings
I-MAB Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/18/2023 | 1096.17% | Cantor Fitzgerald | → $25 | Reiterates | Overweight → Overweight |
| 08/18/2023 | 761.24% | HC Wainwright & Co. | $25 → $18 | Maintains | Buy |
| 08/18/2023 | 1048.33% | Needham | → $24 | Reiterates | Buy → Buy |
| 06/05/2023 | 1048.33% | Needham | → $24 | Reiterates | Buy → Buy |
| 04/19/2023 | 1048.33% | Needham | → $24 | Reiterates | → Buy |
| 04/03/2023 | 1048.33% | Needham | $33 → $24 | Maintains | Buy |
| 04/03/2023 | 1096.17% | Piper Sandler | $30 → $25 | Maintains | Overweight |
| 04/03/2023 | 1096.17% | HC Wainwright & Co. | $45 → $25 | Maintains | Buy |
| 08/31/2022 | 2053.11% | HC Wainwright & Co. | $70 → $45 | Maintains | Buy |
| 08/31/2022 | 1478.95% | Needham | $41 → $33 | Maintains | Buy |
| 08/30/2022 | 1335.41% | Piper Sandler | $35 → $30 | Maintains | Overweight |
| 08/17/2022 | 1861.72% | Needham | $72 → $41 | Maintains | Buy |
| 05/31/2022 | 3249.28% | HC Wainwright & Co. | $80 → $70 | Maintains | Buy |
| 05/31/2022 | 3344.98% | Needham | $85 → $72 | Maintains | Buy |
| 03/30/2022 | 3727.75% | HC Wainwright & Co. | $95 → $80 | Maintains | Buy |
| 11/01/2021 | 3966.99% | Needham | $83 → $85 | Maintains | Buy |
| 09/01/2021 | 4445.45% | HC Wainwright & Co. | $75 → $95 | Maintains | Buy |
| 06/10/2021 | 4206.22% | Cantor Fitzgerald | $76 → $90 | Maintains | Overweight |
| 06/02/2021 | — | Daiwa Capital | Initiates Coverage On | → Buy | |
| 03/15/2021 | 3488.52% | Needham | → $75 | Initiates Coverage On | → Buy |
| 03/03/2021 | 3488.52% | H.C. Wainwright | $55 → $75 | Maintains | Buy |
| 02/25/2021 | 3488.52% | Piper Sandler | → $75 | Initiates Coverage On | → Overweight |
| 12/07/2020 | 2531.58% | HC Wainwright & Co. | → $55 | Initiates Coverage On | → Buy |
| 08/26/2020 | 1876.08% | CMB International | → $41.3 | Initiates Coverage On | → Buy |
| 07/27/2020 | 2292.34% | Cantor Fitzgerald | → $50 | Initiates Coverage On | → Overweight |
| 02/14/2020 | 765.55% | CICC | → $18.09 | Initiates Coverage On | → Outperform |
| 02/12/2020 | 757.89% | China Renaissance | → $17.93 | Initiates Coverage On | → Buy |
| 02/11/2020 | 665.55% | Jefferies | → $16 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月18日 | 1096.17% | 康託·菲茨傑拉德 | →$25 | 重申 | 超重→超重 |
| 2023年08月18日 | 761.24% | HC Wainwright公司 | $25→$18 | 維護 | 買 |
| 2023年08月18日 | 1048.33% | 李約瑟 | →$24 | 重申 | 購買→購買 |
| 06/05/2023 | 1048.33% | 李約瑟 | →$24 | 重申 | 購買→購買 |
| 04/19/2023 | 1048.33% | 李約瑟 | →$24 | 重申 | →購買 |
| 04/03/2023 | 1048.33% | 李約瑟 | $33→$24 | 維護 | 買 |
| 04/03/2023 | 1096.17% | 派珀·桑德勒 | $30→$25 | 維護 | 超重 |
| 04/03/2023 | 1096.17% | HC Wainwright公司 | $45→$25 | 維護 | 買 |
| 2022年08月31日 | 2053.11% | HC Wainwright公司 | $70→$45 | 維護 | 買 |
| 2022年08月31日 | 1478.95% | 李約瑟 | $41→$33 | 維護 | 買 |
| 2022年08月30日 | 1335.41% | 派珀·桑德勒 | $35→$30 | 維護 | 超重 |
| 2022/08/17 | 1861.72% | 李約瑟 | $72→$41 | 維護 | 買 |
| 2022年05月31日 | 3249.28% | HC Wainwright公司 | $80→$70 | 維護 | 買 |
| 2022年05月31日 | 3344.98% | 李約瑟 | $85→$72 | 維護 | 買 |
| 03/30/2022 | 3727.75% | HC Wainwright公司 | $95→$80 | 維護 | 買 |
| 11/01/2021 | 3966.99% | 李約瑟 | $83→$85 | 維護 | 買 |
| 09/01/2021 | 4445.45% | HC Wainwright公司 | $75→$95 | 維護 | 買 |
| 2021/10/06 | 4206.22% | 康託·菲茨傑拉德 | $76→$90 | 維護 | 超重 |
| 06/02/2021 | - | 大和資本 | 開始承保 | →購買 | |
| 03/15/2021 | 3488.52% | 李約瑟 | →$75 | 開始承保 | →購買 |
| 03/03/2021 | 3488.52% | H.C.溫賴特 | $55→$75 | 維護 | 買 |
| 02/25/2021 | 3488.52% | 派珀·桑德勒 | →$75 | 開始承保 | →超重 |
| 12/07/2020 | 2531.58% | HC Wainwright公司 | →$55 | 開始承保 | →購買 |
| 2020/08/26 | 1876.08% | 招商銀行國際 | →$41.3 | 開始承保 | →購買 |
| 07/27/2020 | 2292.34% | 康託·菲茨傑拉德 | →$50 | 開始承保 | →超重 |
| 02/14/2020 | 765.55% | 中金公司 | →$18.09 | 開始承保 | →跑贏大盤 |
| 02/12/2020 | 757.89% | 中國文藝復興 | →$17.93 | 開始承保 | →購買 |
| 02/11/2020 | 665.55% | 傑富瑞 | →$16 | 開始承保 | →購買 |
What is the target price for I-MAB (IMAB)?
天境生物的目標價是多少？
The latest price target for I-MAB (NASDAQ: IMAB) was reported by Cantor Fitzgerald on August 18, 2023. The analyst firm set a price target for $25.00 expecting IMAB to rise to within 12 months (a possible 1096.17% upside). 11 analyst firms have reported ratings in the last year.
康託·菲茨傑拉德於2023年8月18日報道了天境生物(納斯達克代碼：IMAB)的最新目標價。這家分析公司將目標價定為25美元，預計IMAB將在12個月內上漲至(可能上漲1096.17%)。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for I-MAB (IMAB)?
分析師對天境生物的最新評級是多少？
The latest analyst rating for I-MAB (NASDAQ: IMAB) was provided by Cantor Fitzgerald, and I-MAB reiterated their overweight rating.
分析師對天境生物(納斯達克代碼：IMAB)的最新評級由康託·菲茨傑拉德提供，天境生物重申其增持評級。
When is the next analyst rating going to be posted or updated for I-MAB (IMAB)?
下一次分析師對天境生物的評級會在什麼時候發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of I-MAB, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for I-MAB was filed on August 18, 2023 so you should expect the next rating to be made available sometime around August 18, 2024.
分析師在進行了廣泛的研究後得出了股票評級，這些研究包括查閱公開的財務報表，與天境生物的高管和客戶交談，以及收聽財報電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。對天境生物的上一次評級是在2023年8月18日提交的，所以你應該預計下一次評級將在2024年8月18日左右公佈。
Is the Analyst Rating I-MAB (IMAB) correct?
分析師對天境生物的評級正確嗎？
While ratings are subjective and will change, the latest I-MAB (IMAB) rating was a reiterated with a price target of $0.00 to $25.00. The current price I-MAB (IMAB) is trading at is $2.09, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但重申了最新的天境生物評級，目標價在0.00美元至25.00美元之間。天境生物目前的股價為2.09美元，在分析師的預測範圍內。